BioMarin Completes $4.8 Billion Amicus Acquisition

BioMarin Pharmaceutical Inc. has finalized its acquisition of Amicus Therapeutics in an all-cash deal valued at approximately $4.8 billion, marking a significant expansion of its rare disease portfolio. The transaction, priced at $14.50 per share, had been previously announced and is now officially completed.

The acquisition strengthens BioMarin’s position in the treatment of lysosomal storage disorders, a group of rare inherited metabolic diseases. As part of the deal, BioMarin adds several key therapies to its portfolio, including Galafold, the first oral treatment for Fabry disease. Fabry disease is a genetic disorder that leads to the buildup of fatty substances in the body, causing a wide range of complications affecting the heart, kidneys, and nervous system.

In addition, BioMarin gains access to Pombiliti used in combination with Opfolda, a two-component therapy designed to treat Pompe disease. Pompe disease is another rare genetic condition characterized by the accumulation of glycogen in muscle tissues, leading to progressive muscle weakness and respiratory issues. These therapies are expected to complement BioMarin’s existing lineup of treatments targeting rare metabolic conditions.

Beyond approved products, the acquisition also provides BioMarin with U.S. rights to DMX-200, an investigational therapy currently in Phase 3 development for focal segmental glomerulosclerosis (FSGS), a rare and often fatal kidney disease. If successful, DMX-200 could become a first-in-class small molecule therapy for this condition, further enhancing BioMarin’s pipeline.

Company leadership emphasized the strategic importance of the acquisition. BioMarin’s President and CEO, Alexander Hardy, stated that the deal aligns with the company’s long-term strategy to diversify its growth profile while advancing its mission to deliver innovative treatments for patients with rare diseases. He also highlighted BioMarin’s global commercial infrastructure and manufacturing capabilities as key factors that will help expand access to the newly acquired therapies worldwide.

The integration of Amicus’ portfolio is expected to accelerate BioMarin’s growth by broadening its reach across multiple rare disease categories. With this acquisition, BioMarin not only strengthens its commercial offerings but also reinforces its commitment to addressing unmet medical needs in underserved patient populations.

The deal reflects a broader trend in the biotechnology sector, where companies are increasingly pursuing strategic acquisitions to expand their capabilities, pipelines, and global market presence. For BioMarin, the addition of Amicus’ therapies represents a meaningful step toward becoming a more diversified leader in rare disease treatment.